Renal failure · 2025
A practical guide for nephrologist peer reviewers: understanding and appraising Mendelian randomization studies.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Qing Jianbo, Li Yafeng, Soliman Karim M, Cheungpasitporn Wisit
Аннотация
Identifying risk factors for disease onset and progression has been a core focus in nephrology research. Mendelian Randomization (MR) has emerged as a powerful genetic epidemiological approach, utilizing genome-wide association studies (GWAS) to establish causal relationships between modifiable risk factors and kidney disease outcomes. MR uses genetic variants as instrumental variables to infer causal relationships between exposures and disease outcomes. This method leverages the natural randomization of genetic variants to balance confounders, akin to matched cohorts in observational research. The rapid increase in MR studies on kidney disease poses challenges for journals and peer reviewers, especially clinicians unfamiliar with the methodology. High-quality MR studies use strong, well-validated genetic instruments with clear biological relevance, thoroughly testing for pleiotropy and confounding factors using methods like MR-Egger. Sensitivity analyses, such as MR-PRESSO, should ensure findings remain consistent across various assumptions. Effect sizes with confidence intervals should be reported and discussed within established biological mechanisms. Additionally, limitations must be transparently addressed, with recommendations for replication in future studies, to strengthen findings. This article guides readers in understanding MR application in nephrology and identifying high-quality MR studies, helping peers avoid pitfalls while seizing new opportunities in advancing kidney disease research.